Arrowhead Research Corp. (ARWR, Financial) filed Quarterly Report for the period ended 2012-06-30.
Arrowhead Research Corp has a market cap of $36.5 million; its shares were traded at around $2.8 with and P/S ratio of 123.3. Arrowhead Research Corp had an annual average earning growth of 67% over the past 10 years.
Based upon the Companys cash on hand and operating plan at June 30, 2012, and other sources of liquidity, as described above, the Companys management anticipates that the Company will be able to satisfy the cash requirements of its operations through at least the next twelve months. However, the Company anticipates that further equity financings, and/or asset sales and license agreements will be necessary to continue to fund operations in the future.
Revenue associated with research and development funding payments under collaborative agreements is recognized ratably over the relevant periods specified in the agreement, generally the research and development period. Revenue from up-front license fees, milestones and product royalties are recognized as earned based on the completion of the milestones and product sales, as defined in the respective agreements. Payments received in advance of recognition as revenue are recorded as deferred revenue.
The Company recorded revenue of $103,125 during the nine months ended June 30, 2012, as compared to $296,139 during the nine months ended June 30, 2011. The revenue in fiscal 2012 was related to three license agreements acquired in conjunction with the acquisition of Roche Madison Inc. The revenue in fiscal 2011 was related to grants received in the quarter. Revenue for the nine months ended June 30, 2011 associated with Unidym prior to its disposition is presented as a part of discontinued operations.
Read the The complete Report
Arrowhead Research Corp has a market cap of $36.5 million; its shares were traded at around $2.8 with and P/S ratio of 123.3. Arrowhead Research Corp had an annual average earning growth of 67% over the past 10 years.
Highlight of Business Operations:
During the nine months ended June 30, 2012, cash used in operating activities was $10.8 million, which represents the on-going expenses for research and development activities, business development, and corporate overhead. Cash expenses were partially offset by cash received from revenues and other inflows of $0.2 million.Based upon the Companys cash on hand and operating plan at June 30, 2012, and other sources of liquidity, as described above, the Companys management anticipates that the Company will be able to satisfy the cash requirements of its operations through at least the next twelve months. However, the Company anticipates that further equity financings, and/or asset sales and license agreements will be necessary to continue to fund operations in the future.
Revenue associated with research and development funding payments under collaborative agreements is recognized ratably over the relevant periods specified in the agreement, generally the research and development period. Revenue from up-front license fees, milestones and product royalties are recognized as earned based on the completion of the milestones and product sales, as defined in the respective agreements. Payments received in advance of recognition as revenue are recorded as deferred revenue.
The Company recorded revenue of $103,125 during the nine months ended June 30, 2012, as compared to $296,139 during the nine months ended June 30, 2011. The revenue in fiscal 2012 was related to three license agreements acquired in conjunction with the acquisition of Roche Madison Inc. The revenue in fiscal 2011 was related to grants received in the quarter. Revenue for the nine months ended June 30, 2011 associated with Unidym prior to its disposition is presented as a part of discontinued operations.
Read the The complete Report
